NexImmune (OTCMKTS:NEXI – Get Free Report) is projected to issue its resultson Tuesday, May 19th. Analysts expect the company to announce earnings of ($13.25) per share for the quarter.
NexImmune Price Performance
Shares of OTCMKTS:NEXI opened at $0.00 on Tuesday. NexImmune has a 52 week low of $0.00 and a 52 week high of $2.17.
NexImmune Company Profile
NexImmune, Inc is a clinical‐stage biotechnology company focused on developing novel T‐cell immunotherapies to treat cancer, autoimmune disease and persistent viral infections. The company’s core innovation is its proprietary artificial thymic organoid (ATO) platform, which generates naïve T cells capable of recognizing specific antigens. By guiding T‐cell development in vitro, NexImmune aims to create targeted, high‐potency therapeutic candidates that leverage the body’s natural immune response.
The company’s pipeline includes multiple product candidates at various stages of development.
Read More
- Five stocks we like better than NexImmune
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with MarketBeat.com's FREE daily email newsletter.
